Setting 
My Cart
Toggle Nav
Close
  • Menu
  • Setting

Cyclophosphamide

Catalog No.
A2343
An alkylating chemotherapeutic drug that damages DNA through cross-linking, commonly used to construct immunosuppression animal models.
Grouped product items
Size Price Stock Qty
50mg
$50.00
In stock
200mg
$100.00
In stock
500mg
$180.00
In stock
5g
$680.00
In stock
10g
$980.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Cyclophosphamide (CAS 50-18-0) is a synthetic alkylating agent structurally related to nitrogen mustard compounds that acts as a DNA-crosslinking cytotoxic compound in proliferating cells and exhibits immunosuppressive activity in a variety of immune cell populations. In addition, cyclophosphamide is bioactivated in the liver to generate active metabolites that enhance its antitumor effects.

In preclinical and clinical studies, cyclophosphamide induces apoptosis and inhibits cell proliferation, showing significant cytotoxicity against a variety of human tumor cell lines and animal models. It also suppresses humoral and cellular immune responses by interfering with the function and survival of lymphocytes.

In pharmaceutical and clinical applications, cyclophosphamide is widely used to treat malignant tumors, including lymphomas, leukemia, multiple myeloma, breast cancer, and ovarian cancer, as well as in conditioning regimens for bone marrow transplantation. At the same time, by virtue of its potent immunomodulatory effects, cyclophosphamide is an established agent in the management of certain autoimmune diseases.

Cyclophosphamide is widely used to establish immunosuppression animal models; after administration it depletes immune cells and suppresses immune function, and is often used in combination with antigens for immunomodulatory research.

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt261.09
Cas No.50-18-0
FormulaC7H15Cl2N2O2P
SynonymsNSC 26271; Endoxan; Cytoxan; Neosar; Procytox; Revimmune; Cytophosphane
Solubility≥11.85 mg/mL in H2O with gentle warming and ultrasonic; ≥13.05 mg/mL in DMSO; ≥50.8 mg/mL in EtOH
Chemical NameN,N-bis(2-chloroethyl)-2-oxo-1,3,2λ5-oxazaphosphinan-2-amine
Canonical SMILESO=P1(N(CCCl)CCCl)OCCCN1
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment:[1]

Cell lines

9L gliosarcoma cells retrovirally transduced with CYP2B6

Reaction Conditions

1 mM cyclophosphamide for 48 h incubation

Applications

Cyclophosphamide was shown to cause tumor cell death by stimulating apoptosis, as evidenced by the induction of plasma membrane blebbing, DNA fragmentation, and cleavage of the caspase 3 and caspase 7 substrate poly(ADP-ribose) polymerase in drug-treated cells.

Animal experiment:[2]

Animal models

Female C57BL/6 mice, 8 weeks of age

Dosage form

2 mg

Injected intraperitoneally

Applications

Low-dose cyclophosphamide not only decreased the number of regulatory T cells (TREGs), but also led to decreased functionality of TREGs. Cyclophosphamide treatment enhanced apoptosis and decreased homeostatic proliferation of these cells.

Note

The technical data provided above is for reference only.

References:

1. Schwartz PS, Waxman DJ. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Molecular Pharmacology, 2001, 60(6): 1268-1279.

2. Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood, 2005, 105(7): 2862-2868.

Quality Control

User Guide